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Abstract  Obesity  has  become  a  public  health  problem  around  the  world.  According  to  the
Organisation  for  Economic  Co-operation  and  Development  (OECD,  2014  report),  more  than  one
in three  adults  in  Mexico  are  obese.  It  is  known  that  the  hypothalamus,  a  region  of  the  Cen-
tral Nervous  System  (CNS),  is  actively  involved  in  regulating  energy  homeostasis  during  obesity.
Anatomically,  the  hypothalamus  is  composed  of  several  nuclei  coordinating  body  weight  and
metabolism,  including  the  arcuate  nucleus  (ARC),  which  contains  neurons  co-expressing  orexi-
genic peptides  like  Agouti-related  protein  (AgRP),  Neuropeptide  Y  (NPY)  and  the  anorexigenic
peptide Pro-opiomelanocortin  (POMC).  During  obesity,  the  integration  and  metabolic  response
in the  ARC  is  disrupted  by  three  molecular  mechanisms:  (1)  activation  of  endoplasmic  reticulum
(ER) stress,  (2)  mitochondrial  dysfunction,  and  (3)  increase  of  ER  and  mitochondria  contacts,
known as  Mitochondria-Associated  Membranes  (MAMs).  In  this  context,  it  is  proposed  that  MAMs
formation  induces  mitochondrial  Ca2+ overload  and  metabolic  dysfunction,  leading  to  insulin
resistance  and  diabetes.  Recently,  MAMs  formation  has  emerged  as  one  of  the  molecular  mech-
anisms underlying  metabolic  alterations  during  obesity.  Thus,  in  this  review  we  will  focus  on
proposing  scientiﬁc  evidence  to  support  the  role  of  the  MAMs  and  their  function  on  calcium  reg-
ulation during  obesity,  as  an  important  pathological  mechanism  in  the  development  of  diabetes
mellitus type  2.
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besity  represents  one  of  the  diseases  with  the  high-
st  prevalence  worldwide.  The  World  Health  Organization
stimated  that  in  2014  about  13%  of  the  adult  popula-
ion  was  obese  and  the  amount  of  obesity  in  individuals
as  doubled  since  the  1980s.1 In  Mexico,  the  Organiza-
ion  for  Economic  Co-operation  and  Development  (OECD)
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Figure  1  The  arcuate  nucleus  neurons  (ARC)  Neuropeptide
Y/Agouti  related-proteins  (NPY/AgRP)  and  propiomelacortics
(POMC)  coordinate  the  activity  of  the  paraventricular  (PVN)
nucleus,  promoting  the  stimulation  or  inhibition  of  apetite,
respectively.  GABA  is  a  neurotransmitter  released  by  the
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eported  that  approximately  one  in  three  adults  suffers
rom  obesity,2 considering  a  body  mass  index  (BMI)  higher
han  30  kg/m2 to  be  obese.  Usually,  an  increase  in  BMI  is
inked  to  the  excessive  intake  of  high  caloric  foods,  or  a
ecrease  in  catabolism.1--3 However,  this  variable  seems  to
e  multifactorial,  involving  changes  in  behavior,  metabolic,
nvironmental,  genetic,  cultural  and  socioeconomic  factors.
besity  increases  the  possibility  of  developing  cardiovascu-
ar  diseases,  hypertension,  type  2  diabetes,  dyslipidemias,
ome  types  of  cancer,  arteriosclerosis  and  cognitive  dete-
ioration,  affecting  the  patient’s  quality  of  life,1,3,4 thus
aking  the  understanding  of  the  cellular  and  physiological
echanisms  implicated  in  this  pathology  relevant  for  the
evelopment  of  new  treatment  approaches.
Compelling  scientiﬁc  evidence  suggests  that  the  central
ervous  system  (CNS),  and  especially  the  hypothalamus,
re  key  in  the  control  of  energy  homeostasis  because  of
heir  effects  over  of  food  intake  regulation,  lipid  accumu-
ation  in  the  body  and  body  weight.  Therefore,  defects  in
etabolic  integration  involving  insulin,  leptin  and  ghrelin,
t  a  hypothalamus  level,  generate  alterations  in  energy
omeostasis  related  to  the  development  of  obesity  and
ealth  comorbidities.5 The  toxic  effect  associated  with  the
ncrease  of  different  types  of  lipids,  such  as  saturated  fatty
cids  (SFA),  triglycerides  and  ceramides  in  obesity  is  called
ipotoxicity.7--9 In  this  context,  lipids  are  known  to  induce
 failure  in  the  endoplasmic  reticulum  (ER)  and  mitochon-
ria  functions,  promoting  oxidative  stress  in  response  to
n  unfolded  protein  response  (UPR)  exacerbation10--12 as
ell  as  the  development  of  type  2  diabetes  and  metabolic
yndrome.6,12--16
At  a  mitochondrial-associated-membrane  level  (MAM),
besity  regulates  the  communication  between  ER  and  the
itochondria.  In  this  microdomain,  obesity  coordinates  the
ecruitment  of  proteins  in  MAMs  as  well  as  the  Ca2+ ﬂow
etween  ER  and  mitochondria  at  the  hypothalamus  and  liver
evel.17--19
In  this  review,  we  will  discuss  the  role  of  the  hypothala-
us  in  the  regulation  of  energy  consumption  and  its  effect
n  obesity  and  diabetes  development  in  the  context  of  MAMs
emodeling,  alterations  in  Ca2+ homeostasis,  activation  of  ER
tress  and  mitochondrial  function.
he hypothalamus is a brain region which is
ey in the control of energy homeostasis
he  hypothalamus  is  part  of  the  diencephalon,  located  under
he  thalamus  and  formed  by  different  nuclei.  Prominent
mong  these  are  the  preoptic,  paraventricular,  suprachias-
atic,  lateral,  posterior,  mammillary,  dorsomedial  (DMH),
entromedial  (VMH)  and  arcuate  (ARC).  As  a  whole,  the  acti-
ation  of  the  different  nuclei  regulates  energy  homeostasis
hrough  their  action  over  food  intake,  thermogenesis,  and
lucose  balance  in  plasma,  among  other  things.20 In  par-
icular,  DMH,  VMH,  ARC,  the  medial  portion  of  the  lateral
ypothalamus  and  the  ventral  premammillary  nucleus  are
elated  to  the  regulation  of  food  intake.  Therefore,  they
re  called  the  ‘‘satiety  center’’,  while  the  lateral  hypo-
halamus  represents  part  of  the  ‘‘feeding  center’’.20--22,25
ll  these  hypothalamic  nuclei  are  part  of  an  integral  system
t
i
a
tPY/AgRP  neurons,  and  is  very  important  to  the  control  of  food
ntake,  inhibiting  the  anorectic  effects  of  the  POMC  neurons.
alled  the  melanocortin  system  which  modulates  with  the
egulation  of  energy  and  satiety.
The  nuclei  which  form  a  part  of  the  melanocortin  system
ossess  selective  speciﬁcity  for  synthesis  and  the  libera-
ion  of  neuropeptides  and  neurotransmitters  according  to
heir  cellular  type  identity.  Thus,  ARC  is  formed  by  orexi-
enic  neurons  which  express  the  Neuropeptide  Y  (NPY)/the
gouti  related  peptide  (AgRP),  anorexigenic  neurons,  and
roopiomelanocortin  (POMC),  which  release  POMC.  The  lat-
er  is  processed  into  a  melanocytes  -stimulating  hormone
MSH).  NPY/AgRP  and  POMC/MSH  increase  and  decrease
espectively,  in  appetite.22--24 It  is  known  that  the  great-
st  concentrations  of  neurons  expressing  insulin  receptors
s  located  at  the  ARC  level.  ARC  and  its  ﬁbers  project  to  the
araventricular  nucleus  and  periformical  region  (Fig.  1).23
rc  is  found  in  a  privileged  position  within  the  hypothala-
us  since  its  proximity  to  the  median  eminence  (ME)  allows
t  to  sense  hormonal  and  biochemical  factors  of  blood  and
erebrospinal  ﬂuid  with  the  purpose  of  regulating  energy
omeostasis,22,23,25 among  which  leptin,  insulin  and  ghrelin
tand  out.  Leptin  and  insulin,  secreted  by  adipocytes  and  the
ancreas  respectively,  produce  anorexigenic  effects  through
heir  action  over  ARC,  producing  leading  to  an  increase  in
he  genetic  expression  of  NPY/AgRP  and  a  decrease  of  POMC
n  ARC,23,24,26,27,29,30 while  ghrelin,  secreted  by  the  stom-
ch,  promotes  food  intake31,32 through  the  stimulation  of
he  GHSR1  receptor  in  ARC’s  NPY/AgRP  neurons,  inhibiting
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kCalcium  and  Mitochondria-Associated  Membranes  in  metabo
its  activity  through  the  action  of  the  gamma  aminobutyric
acid  (GABA)  neurotransmitter.33--35
Obesity promotes generation of insulin and
leptin resistance
In  animal  models  of  obesity,  induced  by  high-fat  diet  intake
or  in  obese  patients,  the  presence  of  insulin  and  leptin
resistance  has  been  demonstrated.  Insulin  resistance  is  a
key  factor  in  the  development  of  type  2  diabetes  mellitus
(DMT2).36 Physiologically,  the  effects  of  insulin  resistance
are  known  to  be  manifested  in  the  pancreas,  muscle  and
hypothalamus.  Glucose  homeostasis  in  the  body  is  main-
tained  due  to  the  action  of  insulin  on  adipocytes  and  muscle.
At  ﬁrst,  the  pancreas    cells  release  insulin,  which  binds  to
its  receptor  on  the  adipocytes  and  hepatocytes,  and  pro-
motes  the  translocation  of  vesicles  from  the  cytoplasm  to
the  plasmatic  membrane  containing  GLUT-4  transporter.37
Molecularly,  insulin  attaches  to  the    subunit  of  the  insulin
receptor  (IR),  inducing  the  activation  of  the  tyrosine  kinase
domain  in  the  intracellular  portion  of  the    subunit38 and
the  phosphorylation  of  three  tyrosine  residues  (Tyr-1158,
Tyr-1162  and  Tyr-1163).38 The  signal  is  ampliﬁed  through  the
downstream  phosphorylation  insulin  receptor  substrate  type
proteins  (IRS-1,  IRS-2,  IRS-3,  IRS-4),  recruiting  Shc,  growth
factor  2  (Grb2/SOS)  and  regulatory  subunit  p85  of  the  ino-
sitol  phosphatidiyl  3′-kinase  (PI2  kinase).38--42 Amongst  all
these,  PI3K  plays  a  major  role  for  the  activation  of  the
Akt/PKB  and  PKC cascade.  Once  activated,  the  Akt  pro-
tein  induces  glycogen  synthesis  through  the  inhibition  of
the  glycogen  synthase  kinase  protein  (GSK-3),  the  synthesis
of  mTOR  (mammalian  target  of  rampamycin)  core  protein
and  cellular  survival  by  the  inhibition  of  the  apoptosis.39--42
However,  in  insulin-resistant  conditions,  such  as  the  ones
presented  during  lipids  increase  in  obesity,  phosphoryla-
tion  is  inhibited  in  IRS1  tyrosine  and  increasing  307  serine
phosphorylation  of  IRS1.37,43 Pancreatic  cells  respond  by
upregulating  the  synthesis  and  liberation  of  insulin  leading  to
  cells  dysfunction  and  DMT2  development.44 On  the  other
hand,  obesity  also  induces  insulin  resistance  in  the  hypo-
thalamus,  where  the  decrease  in  the  number  of  receptors
to  this  hormone  is  observed.45,46 Altogether,  hyperglycemia
during  obesity  is  linked  to  alterations  in:  (1)  decrease  in
tyrosine  phosphorylation,  (2)  decrease  in  the  number  of
receptors  to  insulin,  and  (3)  increase  in  the  plasmatic  levels
of  insulin.  Furthermore,  an  increase  in  blood  leptin  con-
centrations  has  been  demonstrated  as  a  leptin-resistance
index  in  obese  patients  and  obesity-induced  murine  models
by  high-fat  diet  intake.28 Leptin  signalling  pathway  is  acti-
vated  by  leptin  binding  to  its  receptor  and  the  downstream
activation  of  Janus  (JAK)  kinases  by  transducers  and  acti-
vators  of  transcriptions  (STAT),  MAPK  and  IRS1.47,48 In  the
context  of  obesity,  leptin  resistance  is  linked  to  the  reduced
activity  of  the  transductor  and  the  phosphorylated  activa-
tor  of  transcription  3  (STAT)48,49 and  to  the  no-activation  of
genes  of  the  cytokine  suppressors  family  (SOCS).49 In  fact,
it  has  been  recently  demonstrated  that  leptin  and  insulin
act  as  a  whole  on  hypothalamic  neurons,50 suggesting  that
obesity  affects  hypothalamic  circuits  and  compromises  the
hormonal  integration  implicated  in  the  coordination  of  ener-
getic  metabolism.
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Additionally,  the  effect  of  these  hormones  on  body  phys-
ology  not  only  relates  to  obesity  problems,  but  also  to  the
evelopment  of  hypertension  in  mice  and  humans51--53 and
lzheimer’s  susceptibility.54 Thus,  the  mechanisms  which
nderlie  the  functional  alterations  of  the  hypothalamus  dur-
ng  obesity  might  be  implicated  in  additional  pathologies  in
umans.
lterations in the endoplasmic reticulum and
itochondria function during obesity promote
nsulin and leptin resistance
ifferent  studies  have  provided  substantial  evidence  that
besity  induces  endoplasmic  reticulum  (ER)  stress  and  mito-
hondrial  dysfunction  into  organs  which  are  metabolically
elevant  for  the  coordination  of  energetic  balance.  ER  is  a
etwork  of  membranous  tubes  and  ﬂattened  sacs  which  is
resent  in  all  eukaryotic  cells,  involving  synthesis,  folding,
aturation  and  trafﬁc  of  proteins,  as  well  as  storage  and
omeostasis  of  Ca+2 and  lipid  biosynthesis.12,15,55,56 Proteins
nter  into  the  ER  lumen  as  unfolded  polypeptide  chains  and
hey  fold  in  the  interior  to  make  a more  stable  formation.
hen  the  proteins  are  misfolded,  they  overload,  and  the
xpression  of  chaperones  is  activated  with  the  inability  to
ontrol  its  accumulation,  with  the  objective  of  stimulating
he  unfolded  protein  response  (UPR).  Protein  synthesis,  and
ts  translocation  toward  ER,  are  reduced  in  this  process,  and
PR  genes  are  activated  to  increase  the  ability  of  ER  to  ﬁx
isfolded  proteins.  If  homeostasis  cannot  be  reestablished,
 mechanism  of  cell  death  by  apoptosis  is  stimulated.12,15,57
his  regulation  mechanism  is  very  active  and  especially
mportant  in  secreting  cells41 such  as  neurons.11
R’s stress sensors and UPR onset
he  increase  of  misfolded  proteins  in  ER  is  well-known  to
roduce  stress,  which  may  be  measured  by  select  mem-
rane  protein  groups  called:  IRE,  PERK  and  ATF6.58,59 Ire1,
s  well  as  Ire1, break  the  ARNm  of  the  X-box  binding  protein
XBP1)  generating  XBP1  splicing  (sXBP1).59 sXBP1  activates
he  expression  of  genes  which  codify  for  the  synthesis  of
haperones,  components  of  the  degradation  of  ER  associ-
ted  with  protein  degradation  (ERAD)  and  genes  in  charge
f  phospholipid  biosynthesis  and  autophagy.60--62 The  PERK
omplex  phosphorylates  the  translation  initiation  factor
IF2a,  dimming  translation,  yet  boosting  ATF4  translation,
hich  regulates  genes  with  secretor  functions  and  of  the
poptotic  type  included  in  the  C/EBP  homologous  (CHOP)
rotein.60,62 ATF6  is  an  activator  factor  which  travels  to  the
olgi  apparatus  in  response  to  stress,  where  it  undergoes
roteolysis,  liberating  its  cytosolic  domain,  called  the  bZip
ranscription  factor,  which  enters  the  nucleus  and  activates
he  UPR  genes  involved  in  protein  folding,  processing  and
egrading.60 The  chaperones  which  regulate  the  proper  pro-
ein  folding  are  the  proteins  related  to  GRP78  glucose,  also
nown  as  heavy  chain  binding  immunoglobulin  proteins,58rotein  disulﬁde-isomerase  (PDI),  calnexin  (CANX),  calreti-
ulin  (CALR)  and  GRP94.59 In  this  context,  BiP  binds  to  Ire1,
TF6  and  PERK  domains  and  dissociates  after  ER  stress  induc-
ion,  suggesting  that  unfolded  proteins  compete  for  BiP,
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Figure  2  Misfolded  Protein  Response  (MPR).  When  the  ﬂow  of  misfolded  proteins  to  the  ER  is  increased,  the  BIP  protein  chaperone
is released  from  IRE-1,  PERK  and  ATF6,  allowing  it  to  act  as  a  transcription  factor  and  allowing  chaperone  proteins  synthesis,  which
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llowing  the  oligomerization  and  activation  of  these  sensors
Fig.  2).51,60,61
ipid accumulation during obesity creates ER
tress inducing hypothalamic inﬂammation
nd the generation of diabetes
pidemiological  data  conﬁrms  a  strong  link  between  the
ncrease  in  the  level  of  obesity  and  the  development  of
ype  2  diabetes;  indicating  that  for  every  kilogram  of  gained
eight,  at  the  population  level,  there  is  a  linear  increase  in
he  diabetes  rate.3 Experimental  evidence,  in  obese  humans
nd  animal  models  with  obesity,  suggests  that  the  escape
f  lipids  from  adipose  tissue  and  ectopic  accumulation  of
eramides  (a  type  of  sphingolipid),  acylcarnitines,  diacyl-
lycerols  and  AGS  cause  tissue  damage  to  metabolically
elevant  organs,  including  the  skeletal  muscle,  liver,  pan-
reatic  beta  cells,  myocardium  and  brain,  in  an  event  called
ipotoxicity.63--65 The  lipotoxic  effect  is  largely  determined
ecause  every  organ  has  its  own  lipid  proﬁle.  Hence,  selec-
ive  changes  in  lipid  species  in  different  organs  may  be
elevant  to  the  development  of  lipotoxicity.  In  this  context,
t  is  known  that,  physiologically,  C18:0  type  ceramides  are
ssential  for  cerebellar  development  and  C22:0-24:0  regu-
ates  hepatic  function,63,64 while  saturated  diacylglycerols
nd  lipids  take  part  in  intracellular  signaling  processes  in
any  cellular  types  of  the  body.65 In  this  regard,  it  has  been
D
o
t
cuggested  that  during  obesity  new  species  of  lipids,  which
re  potentially  toxic  for  the  body’s  organs,  are  produced,
ncluding  ceramides,  cholesterol,  AGS  and  diacylglycerols.
ll  these  species  are  known  to  inhibit  insulin  sensitivity  in
ellular  cultures  and  animal  models.66 Saturated  ceramide
nd  lipid  accumulation  has  even  been  detected  in  the
keletal  muscle  of  obese  humans,  which  correlates  to  a
eneration  of  insulin  resistance.66,67 Of  note,  ceramides,
holesterol,  saturated  DAG  and  lipids  activate  the  ER’s  stress
n  the  hypothalamus  in  animal  models,  generating  insulin
esistance.9,11,66,68
Notably,  a  close  connection  is  known  to  exist  between  the
R  stress  activation  and  inﬂammation.  Experimental  work
hows  that  Jun-N  terminal  kinase  (JNK  activating  protein  1
-  AP1-),  activated  during  the  ER’s  stress  promotes  the  activ-
ty  of  the  IKKB/NF-B  pathway.69 De  Sousa  et  al.  (2005),
roved  that  high  fat  diet-induced  obesity  increases  the  TNF
evels  and  other  pro-inﬂammatory  cytokines  in  serum  of
nimal  models  of  obesity.45 In  contrast  with  unsaturated
ipids,  intra-cerebrovascular  infusion  of  saturated  lipids  and
almitic  acid  cause  inﬂammation  and  insulin  resistance,
hich  is  a  IKK-kinase  dependent  pro-inﬂammatory,70 pre-
umably  through  the  activation  of  TLR4  recetors.71,72 In
his  context,  the  increase  of  SFA,  cholesterol,  triglycerides,
AGs  and  ceramides  during  obesity  causes  the  activation
f  ER  stress  and  inﬂammation,  inducing  the  insulin  resis-
ance  state  in  the  hypothalamus  and  generating  metabolic
omplications.
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Lipotoxicity linked to lipid increase during
obesity produces mitochondrial dysfunction,
insulin resistance and the development of
diabetes
Mitochondria  represents  pivotal  intracellular  organelles  in
charge  of  ATP  synthesis  through  oxidation  of  energetic  sub-
strates  and  cellular  processes,  including  cell  differentiation
and  cellular  death,  and  help  maintain  growth  control  and
the  cellular  cycle.73 Defects  in  mitochondrial  function  leads
to  a  metabolic  deterioration  increasing  susceptibility  to  the
development  of  type  II  diabetes  mellitus  or  obesity.74
Different  studies  on  the  muscle  of  obese  humans  with
a  insulin  resistance  state  have  shown  that  the  presence
of  mitochondrial  dysfunction,  including  low  oxidative  enzy-
matic  activity  and  a  decrease  in  lipid  metabolism  compared
to  thin  subjects.75 Furthermore,  SFA  increase  during  obe-
sity  correlates  with  primary  defects  of  the  mitochondrial
oxidative  capacity  of  the  muscle,  liver  and  adipose  tis-
sue,  promoting  DAG  increase  and  insulin  resistance.76 These
events  are  closely  linked  with  the  increase  in  T2DM.73,77
A  big  part  of  the  lipotoxic  effect  of  lipids  over  the  mito-
chondrial  function  is  because  its  accumulation  produces
reactive  oxygen  species  (ROS),  including  anion  superox-
ide  (O2−),  hydrogen  peroxide  (H2O2)  and  hydroxyl  radical
(OH−).73 A  fatty  dietary  intake  in  mice  has  been  proven
to  increase  ROS  production  in  the  liver  and  adipocytes
and  precedes  TNF increase  in  blood  and  liver.78 A  sim-
ilar  effect  has  been  found  in  the  hypothalamus  of  rats
with  acute  hypertriglyceridemia,  caused  by  intraperitoneal
or  intra-cerebrovascular  injections  of  20%  lipids  including
a  combination  of  soy  oil,  glycerin  and  phospholipids.79 In
this  context,  we  were  able  to  demonstrated  the  lipotoxic
neuronal  damage  at  metabolic  center  regulator  caused  by
the  injections  of  lipids  and  promoting  the  consumption  of
food.79 This  effect  seems  to  be  linked  to  ROS  increase  in
the  POMC  neurons  of  the  hypothalamus,  which  produce
satiety,  hence  the  suggestion  that  POMC  neurons  are  more
sensitive  to  lipotoxic  damage  caused  by  ROS  compared  to
NPY/AgRP  neurons.  Conversely  to  these  events,  the  admin-
istration  of  complex  antioxidants  prevents  ROS  formation
and  inhibits  appetite,  in  part  by  inducing  the  expression
of  POMC  in  ARC.80 Consequently,  mitochondrial  dysfunction
linked  to  the  development  of  obesity  modulates  food  intake
and  sensitivity  to  insulin,  coordinating  the  development
of  T2DM.
By  now,  the  cause  of  mitochondrial  damage  during  obe-
sity  and  its  effect  on  insulin  sensitivity  is  unknown.  In
fact,  mitochondrial  dysfunction  is  proposed  to  be  a  con-
sequence  and  not  a  cause  of  insulin.  This  is  based  on  the
fact  that  alterations  in  the  mitochondrial  function  in  diverse
models  do  not  decrease  insulin  sensitivity.81 Even  the  lipid
infusion,  which  promotes  insulin  resistance,  increases  beta
oxidation  in  humans  and,  contrarily,  an  increase  in  insulin
sensitivity  by  sensitizing  agents  (metformin,  TZD,  among
others)  inhibits  ATP  production  in  the  mitochondria.81 In  any
case,  accumulated  experimental  evidence  during  the  last
decade  of  research  have  give  us  substantial  support  propos-
ing  that  mitochondria  seems  to  coordinate  the  development
of  metabolic  complications  linked  to  obesity,  either  promot-
ing  or  inhibiting  lipotoxic  damage.
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Certainly,  it  is  necessary  to  conduct  further  integral
esearch,  which  will  determine  whether  or  not  mito-
hondrial  dysfunction  during  obesity  is  a  cause  or  the
onsequence  of  the  metabolic  imbalance  which  facilitates
he  development  of  T2DM  in  humans.
ipids accumulation during obesity modulate
AMs formation and coordinate the
evelopment of diabetes
R  and  the  mitochondria  interact  metabolically  and  func-
ionally  through  links  between  its  membranes  known
s  MAMs.82,83 Its  function  has  been  related  to  ER’s
hospholipids  import  to  the  mitochondria,  the  cellular
esponse  between  the  ER  and  mitochondria,  and  cell
urvival  and  death.17,84 MAMs  constitute  a  microdomain
hich  recruits  different  proteins  of  functional  impor-
ance,  among  them:  (1)  enzymes  which  participate  in  the
ynthesis  of  lipids  (acyltransferase  cholesterol,  diacylglyc-
rol  acyltransferase  and  phosphatidylserine  synthase),84
2)  calcium-regulator  proteins  (inositol-1,4,5-tris  phosphate
eceptor  (IPR),  ryanodine  receptor  (RyR),  the  voltage-
ependent-anion-mitochondrial-channel-1protein  (VDAC1)
nd  the  sigma-1receptor  (SigR1)),  (3)  proteins  which  par-
icipate  in  protein  folding  (calnexin  (CNX)  and  ERO  1L-),84
4)  proteins  involved  in  mitochondrial  remodeling  (dynamin-
ike  1  (DPR1)  and  mitofusins  1  and  2  (MFN  1  and  2)),  and  (5)
he  ER  binding  stabilizing  proteins,  PACS2  (Fig.  3).84
The  interaction  between  ER  and  the  mitochondria  has
een  recently  proven  to  be  regulated  by  the  action  of
FN  1  and  2  (Fig.  3).84 It  has  been  proven  that  ﬁbro-
lasts  which  do  not  express  MFN2  display  a  reduction  in
he  contacts  between  ER  and  the  mitochondria,  which
ecover  when  the  MFN2  expression  is  reestablished  in
R  through  genetic  manipulation.85 Functional  integration
hrough  MAMs  allows  calcium  homeostasis  regulation  in
he  cell.  In  base  conditions,  Ca2+ concentration  in  the
ell’s  cytosol  (free  100  nM  Ca2+ versus  100  mM  in  extra-
ellular  space)  is  maintained  through  active  participation
f  the  ER  and  the  mitochondria.  Cytosolic  Ca2+ is  cap-
ured  to  the  ER  by  the  action  of  the  SERCA  bomb  and  is
aken  by  buffering  molecules  such  as  calsequestrin.86 Under
timulation  conditions,  Ca2+ is  released  from  ER  by  the
yanodine  receptor,  activated  by  very  low  cytosolic  Ca2+
oncentrations,  or  through  IP3R  receptors  (abundantly  con-
entrated  in  MAMs)66 in  response  to  phosphatidylinositol
ignals,  produced  when  Ca+2 concentrations  are  low.86 Ca2+
eleased  through  IP3R  ﬂows  to  the  mitochondrial  matrix
hrough  mitochondrial  calcium  uniporter  proteins  (MCU),82
ctivating  mitochondrial  dehydrogenases  activity  which  are
 key  element  in  ATP  production.82,87 Nevertheless,  an
ncrease  in  ER’s  calcium  ﬂow  to  the  mitochondria  through
P3R  promotes  mitochondrial  damage  and  apoptosis.87 In
act,  MFN1,  MFN2,  phosphatidylinositol-3,4,5-triphosphate
-phospatase  (PTEN),  promyelocytic  leukemia  (PML)  and  RE
-  oxydoreducin  chaperone  proteins  (ERO-1  L-)  increase
R  calcium  release  to  the  mitochondria,  either  phosphory-
ating  or  interacting  with  IP3R.88--92
Calcium  decrease  at  the  ER  level  creates  ER  stress
ctivation,  including  morphologic  changes  and  an  ER-
itochondrial  bind  increase,93 leading  to  an  increase  in
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pigure  3  The  Mitochondria-Associated  Membranes  (MAMs)  are
f calcium  homeostasis,  transport  of  lipids,  mitochondrial  morp
een associated  with  the  coordination  of  energetic  metabolism
itochondrial  activity.93 It  has  been  noted  that  defects  in
AMs  microdomains’  proteins  have  been  proven  to  promote
R  stress  previous  to  the  development  of  mitochondrial
ysfunction.41 This  way,  it  is  possible  for  defects  in  the
onformation  of  MAMs  to  lead  to  alterations  in  calcium
omeostasis  or  metabolic  damage  linked  to  ER  stress,  induc-
ng  a  mitochondrial  dysfunction.  In  this  context,  MFN2
eletion  in  rats  and  mice  promotes  insulin  resistance  and
itochondrial  dysfunction  linked  to  ER  stress  activation  in
keletal  muscle77,94 and  liver95,96 and  a  decrease  in  MTF2
xpression  was  proven  in  obese  patients.  It  is  worth  stressing
hat  obesity  induced  by  high-fat  dietary  intake  in  mice  who
acked  MFN2  in  anoerxigenic  POMC  neurons  of  the  hypothal-
mus,  created  a  decrease  in  ER  and  mitochondria  contacts,
esulting  in  ER  stress,  leptin  resistance  and  a  reduced  energy
xpenditure.17 Contrarily,  obesity  induced  by  a  high-fat  diet
ntake  in  mice  who  lacked  MFN1  and  MFN2  in  AgRP  orexi-
enic  neurons  of  the  hypothalamus  promoted  a  decrease  in
R  and  mitochondria  contacts,  obesity,  and  increase  in  par-
ial  fat.18 Molecularly,  it  is  suggested  that  an  increase  in  ER
nd  mitochondria  contacts  coordinated  by  MFN2  during  obe-
ity,  increase  Ca2+ ﬂows  from  ER  to  the  mitochondria  through
P3R  receptors,  generating  mitochondrial  dysfunction,  acti-
ation  of  the  JNK  pathway  and  insulin  resistance19 (Fig.  4).
ll  together,  it  seems  that  MAMs  closely  coordinate  energy
etabolism  through  their  defects  over  calcium  homeostasis,
R  activation  and  mitochondrial  function,  molecular  pro-
esses  which  are  compromise  during  lipotoxicity  induced  by
ipids  accumulation  during  obesity.97
trategies for obesity treatment and its
ffects in patients
iven  the  effect  of  obesity  in  the  development  of  comorbidi-
ies,  different  strategies  have  been  used  with  the  purpose
I
t
ticrodomain  made  up  of  different  proteins  which  are  in  charge
gy  and  the  oversight  of  cellular  death.  Their  work  has  recently
f  inducing  weight  loss  and  its  effect  on  the  improvement
f  glycemic  control  in  obese  subjects  with  T2DM.98,99 How-
ver,  keeping  the  weight  off  represents  a  greater  challenge
n  obesity  treatment.100 To  this  end,  different  interventions
ave  been  employed,  such  as  diets,  pharmacological  treat-
ents  and  surgery.  As  an  example  of  the  ﬁrst  intervention,
n  a  meta-analysis  study  using  data  from  the  Cochrane  Cen-
ral  Register  of  Controlled  Trials  and  EMBASE  from  January
981  to  February  2013,  anti-obesity  drugs,  food  replace-
ent  and  high-protein  diets  were  proven  to  be  linked  to
eight-loss  maintenance  compared  to  food  supplements
nd  exercise.100 On  the  other  hand,  pharmacological  treat-
ent  has  not  been  so  successful,  in  part  due  to  its  limited
uccess  in  the  long  term  and  lack  of  effect  when  the  con-
umption  is  stopped,  also  the  development  of  major  side
ffects.101,102 One  example  in  this  scenario  is  the  Fen-
hen  (Fenﬂuramine/phentermine,  serotonin/noradrenaline
eleasers),  withdrawn  from  the  market  in  1997  because  of
ts  side  effects,  which  included  valve  disease  and  pulmonary
ypertension,  and  rimonabant  (CB1  receptor  antagonist),
ithdrawn  from  the  market  in  2008  because  of  its  pos-
tive  effect  on  the  generation  of  severe  depression  and
uicides.101 As  a third  intervention,  there  is  bariatric  surgery,
hich  has  proven  to  be  effective  in  weight  loss  and  even
emitting  T2DM  or  improving  glucose  levels  in  patients  for
ver  two  years.103 We  will  now  describe  the  effect  of
aid  intervention  on  the  nervous  system  for  the  control  of
etabolism.
ariatric surgery and its effect  on the CNS for
romoting weight losst  is  well-known  that  not  all  patients  who  lose  weight  in
he  obesity  context  are  able  to  keep  the  weight  off  in
he  long  term.  For  example,  in  the  US,  approximately  1
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oFigure  4  The  development  of  obesity  promotes  an  increase  
mitochondria  Ca2+ overload  and  oxidative  damage  and  inﬂamm
in  every  6  subjects  can  maintain  the  loss  of  10%  weight  in
the  long  term,  the  rest  suffer  a  relapse  and  continue  to  be
at  risk  of  T2DM  generation.104 Since  its  beginnings  in  the
50s,  bariatric  surgery,  including  Roux-en-Y  gastric  bypass
(RYGB),  adjustable  gastric  band  (AGB)  and  biliopancreatic
diversion  have  been  the  most  effective  interventions  for  the
treatment  of  obesity  in  a  population  with  morbid  obesity
(BMI  ≥40  or  ≥35).105,106 These  surgeries  allow  weight  loss
through  caloric  restriction  and/or  malabsorption  of  calories
and  reverts  or  reduces  comorbidities  like  T2DM,  hyperten-
sion  and  hyperlipidemia,  among  others.105,107
Interestingly  enough,  the  effect  of  bariatric  surgery
intervention  has  over  the  nervous  system’s  ability  to  reg-
ulate  the  metabolism  of  the  body  has  recently  been
demonstrated.  Studies  have  shown  high  activity,  speciﬁcally
in  the  hypothalamus  region  of  the  brain  of  women  who  have
undergone  RYGB  surgery  when  they  are  shown  images  of
hyper-caloric  food,  regarding  non-obese  women,  which  cor-
relate  with  a  low  score  in  hunger  and  a  high  score  in  satiety
compared  to  those  with  normal  and  obese.108 Molecularly,
the  melanocortin  4  receptor  (MC4R)  has  been  proven  to  be
a  target  responsible  for  weight  maintenance  in  individuals
who  are  heterozygous  for  this  gene.109
Also,  even  though  bariatric  surgery  allows  for  the  reduc-
tion  of  body  weight,  its  effect  in  the  long  run  depends  in
large  part  on  obese  subjects.  The  reason  for  this  effect  may
be  linked  to  a  change  in  hormone  liberation  from  the  intes-
tine  and  stomach,  which  regulates  the  body  metabolism.
RYGB  and  VSG  bariatric  surgeries  are  known  to  increase  the
release  of  pepri  YY  (PYY),  released  by  L  cells  from  the  distal
small  intestine,110,111 but  it  does  not  have  an  effect  during
caloric  restriction  or  due  to  a  gastric  band  surgery.106,112,113
Weight  loss  is  greater  in  patients  who  underwent  RYGB
surgery  and  who  present  an  increase  in  PYY.114,115 PYY  has
O
c
otween  ER  and  mitochondrias  contacts  in  the  liver,  leading  to
 generation.
n  anorexigenic  effect,  acting  at  a  solitary  tract  nucleus  and
RC  level116 to  promote  an  increase  in  energy  expenditure
nd  delay  stomach  emptying.117 Another  peptide  secreted
y  L  cells  is  GLP-1  (glucagon-like  peptide-1),  which  inhibits
lucagon  release  and  slows  gastric  emptying,  also  reducing
ood  intake  by  stimulating  the  hypothalamus  and  brain  stem
ormones,  among  other  regions  of  the  brain  like  striatum
nd  black  matter.106,118 GLP-1  has  shown  similar  responses
o  PYY  after  RYGB  and  VSG  surgeries.106,119A  third  hormone
hich  suffers  changes  after  gastric  surgery  is  ghrelin,  which
s  released  from  the  stomach  and  inhibits  food  intake,  induc-
ng  the  activation  of  the  hypothalamus.  Ghrelin  is  reduced
fter  VSG  surgery,120 increases  after  gastric  band  surgery
nd  remains  without  changes,  increases  or  decreases,  after
YGB.106,121,122
Finally,  basic  science  experiments  have  shown  non-
onclusive  target  results  additional  to  the  effect  of  the
ariatric  surgery  over  the  nervous  system  function.  Among
hem,  reports  suggest  that  there  are  not  any  changes  in
he  neuropeptide  expression  which  promotes  food  intake,
ncluding  AgRP  and  NPY,123 while  other  reports  show
 decrease  in  NPY  expression,124 or  an  NPY  and  AgRP
ncrease.125 All  together,  more  evidence  is  required  to  con-
lusively  determine  the  effect  of  bariatric  surgery  over  body
eight  regulation  through  the  anorexigenic,  orexigenic  neu-
opeptides  and  GLP-1  function  expressions  in  the  CNS.
ossible strategies for MAMs remodeling as
besity treatmentne  of  the  most  outstanding  pharmacological  strategies  to
ontrol  lipotoxic  damage  induced  during  obesity  is  the  use
f  chemical  chaperones.  Chemical  chaperones  are  agents
3w
t
l
d
t
i
w
a
R
a
t
i
a
h
c
B
s
t
i
u
s
T
a
t
d
t
i
i
C
P
m
e
a
o
b
i
m
E
t
t
c
a
c
l
t
l
W
i
o
a
t
t
ﬁ
C
T
F
C
R
;0  
hich  avoid  ER  stress  and  improve  mitochondrial  func-
ion.  These  chaperones  produce  changes  in  MAMs  proteins,
owering  of  the  binds  between  ER  and  the  mitochon-
ria,  the  increase  of  oxidative  stress  and  Ca2+ ﬂow  to
he  mitochondria.19 In  mice  models,  chemical  chaperones
ncluding  4-phenyl  butyric  acid  (4-PBA),  a  low-molecular-
eight  molecule,  and  taurine  ursodeoxycholic  conjugate
cid  (TUDCA),  an  endogenous  biliary  salts  derivate,16 and
,  S-O-(3-piperidino-2-hydroxy-1-propil)-dihydrochloride  of
midoxime  nicotinic  acid  (BGP-15),  have  shown  to  be  effec-
ive  in  protecting  against  the  ER  stress  activation  favoring
nsulin  sensitivity.  In  this  context,  results  in  cellular  culture
s  well  as  in  genetic  animal  models  of  obesity  (mice  ob/ob),
ave  show  that  chaperones  reduce  ER  stress,  normalize  glu-
ose  levels  and  increase  insulin  sensitivity.16 In  particular,
GP-15  is  the  most  promising  candidate  to  improve  insulin
ensitivity,  since  it  is  comparable  to  other  insulin  sensitizers
ested,  like  rosiglitazone,126 in  addition  to  having  effects
n  patients  with  diabetes.127 Other  new  drugs  which  mod-
le  ER  stress  response  are  being  tested  in  animal  models,
uch  as  celastrol,  which  is  a  molecule  extracted  from  the
ripterygium  wilfordii  plant  that  reduces  ER  stress  and  acts
s  a  leptin  sensitizer,  and  has  great  potential  as  anti-obesity
herapeutic  agent.128
Even  though  it  has  not  been  proven  in  humans,  evi-
ence  suggests  that  protein  modulation,  which  comprises
he  MAMs  microdomain,  may  be  a  therapeutic  target  to
mprove  metabolism  and  reduce  oxidative  stress  and  the
nﬂammatory  response  observed  in  obesity.129
onclusions
OMC  and  AgRP  neurons  of  the  ARC  nucleus  of  hypothala-
us  represent  a  functional  node  which  regulates  corporal
nergy  homeostasis  and  is  the  target  of  pathological  alter-
tions  during  obesity  which  predispose  to  the  development
f  diabetes.  One  of  the  most  signiﬁcant  alterations  caused
y  obesity  is  the  increase  of  lipids,  which  generates  changes
n  MAMs  proteins  recruitment  and  spatial  conformation,  pro-
oting  ER  stress  and  an  increase  in  calcium  ﬂow  between
R  and  the  mitochondria.  ER  stress  activation  is  known
o  be  linked  to  ROS  increase  and  inﬂammation,  which  in
urn  promotes  the  development  of  insulin  resistance,  glu-
ose  intolerance  and  diabetes.  A  strategy  to  revert  these
lterations  is  through  bariatric  surgery,  since  it  promotes
hanges  in  hormones  released  in  the  intestine  like  PYY,  ghre-
in  and  GLP-1.  Another  strategy  which  may  be  available  in
he  future  for  obese  patients  is  chemical  chaperones,  which
ower  ER  stress  and  improve  insulin  and  leptin  sensitivity.
e  suggest  that  changes  or  alterations  in  MAMs  remodel-
ng  represent  a  pathological  mechanism  in  the  context  of
besity,  where  molecular  systems  implicated  in  ER  stress
ctivation  and  mitochondrial  function  contribute  to  the  con-
rol  of  metabolic  homeostasis.  Thus,  thoroughly  addressing
he  characterization  of  MAMs  microdomain  may  enable  us  to
nd  new  therapeutic  targets  for  obesity  treatment.onﬂict of interest
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